Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
10.79
+0.03 (0.28%)
At close: May 16, 2025, 4:00 PM
10.62
-0.17 (-1.58%)
After-hours: May 16, 2025, 7:51 PM EDT
Roivant Sciences Employees
Roivant Sciences had 908 employees as of March 31, 2024. The number of employees increased by 4 or 0.44% compared to the previous year.
Employees
908
Change (1Y)
4
Growth (1Y)
0.44%
Revenue / Employee
$135,006
Profits / Employee
-$128,437
Market Cap
7.70B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ROIV News
- 2 days ago - Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 - GlobeNewsWire
- 24 days ago - Roivant Sciences: Primed For Growth With A De-Risked Pipeline - Seeking Alpha
- 26 days ago - Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 - GlobeNewsWire
- 2 months ago - Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies - GlobeNewsWire
- 2 months ago - Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - GlobeNewsWire
- 2 months ago - Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - GlobeNewsWire
- 3 months ago - Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update - GlobeNewsWire